Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 781 to 795 of 1136 results for pain

  1. Violence and aggression: short-term management in mental health, health and community settings (NG10)

    This guideline covers the short-term management of violence and aggression in adults (aged 18 and over), young people (aged 13 to 17) and children (aged 12 and under). It is relevant for mental health, health and community settings. The guideline aims to safeguard both staff and people who use services by helping to prevent violent situations and providing guidance to manage them safely when they occur.

  2. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)

    Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.

  3. Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.

  4. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

    Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

  5. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.

  6. What is the clinical and cost effectiveness of carbamazepine as initial treatment for trigeminal neuralgia compared with other pharmacological treatments?

    Source guidance details Comes from guidance Neuropathic pain in adults: pharmacological management in non-specialist settings Number

  7. Moderate to severe acute post­-operative pain: sufentanil sublingual tablet system (ESNM71)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

  8. Irreversible electroporation for treating pancreatic cancer (IPG579)

    Evidence-based recommendations on irreversible electroporation for treating pancreatic cancer. This involves inserting special needles into the tumour in the pancreas and using short electrical pulses to destroy the cancer cells.

  9. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries (IPG762)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries. This involves keyhole abdominal surgery. The aim is to stimulate and possibly strengthen the diaphragm to help people breathe without a ventilator.

  10. Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (IPG653)

    Evidence-based recommendations on valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic valve dysfunction in adults. This involves placing a new bioprosthetic valve inside a failing bioprosthetic valve.

  11. Inflammatory bowel disease (QS81)

    This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.

  12. Carbamazepine for treating trigeminal neuralgia:- What is the clinical and cost effectiveness of carbamazepine as initial treatment for trigeminal neuralgia compared with other pharmacological treatments?

    Source guidance details Comes from guidance Neuropathic pain in adults: pharmacological management in non-specialist settings Number

  13. High-intensity focused ultrasound for prostate cancer (IPG118)

    Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.

  14. Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)

    Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer in adults who have not had chemotherapy.

  15. Pegaspargase for treating acute lymphoblastic leukaemia (TA408)

    Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia.